Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CHILDREN S CETIRIZINE HYDROCHLORIDE ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CHILDREN S CETIRIZINE HYDROCHLORIDE ALLERGY.
ACUVUE THERAVISION WITH KETOTIFEN vs CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Cetirizine is a selective antagonist of peripheral histamine H1 receptors. It inhibits the H1 receptor-mediated effects of histamine, reducing symptoms such as pruritus, sneezing, rhinorrhea, and urticaria. It also decreases eosinophil chemotaxis and adhesion molecule expression.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
5-10 mg orally once daily; max 10 mg/day. For children's formulation, typical adult dose applies to patients >12 years.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Approximately 8.3 hours (range 6–10 hours) in healthy adults; prolonged in renal impairment (e.g., up to 20 hours).
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Renal: ~60% unchanged; fecal: ~10%; minor biliary elimination.
Category A/B
Category A/B
Antihistamine / Mast Cell Stabilizer
Antihistamine